Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows significant upside potential, with a mean price target of $18.43 indicating a 70.3% increase from the current price of $10.82 [1] Price Target Analysis - The average price target consists of seven estimates ranging from a low of $11 to a high of $26, with a standard deviation of $4.50, suggesting variability in analyst opinions [2] - The lowest estimate indicates a modest increase of 1.7%, while the highest suggests a substantial upside of 140.3% [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [7] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ARQT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 12.4%, with two estimates moving higher and no negative revisions [10] - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [11]